John Kozlovsky
Ophthalmology · San Antonio, TXNPI 1063401255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $316 and has fallen 78.3% since, to $69 in 2025. That places this record below the midpoint for ophthalmology clinicians in TX, where the typical reported total is $1,835.
Across 44 payments — averaging $29.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$212
- AbbVie$145
- NEW World Medical,inc.$138
- Genentech USA, Inc.$125
- Bausch & Lomb Americas Inc.$117
- Ocular Therapeutix, Inc.$111
- plus $436 from 10 others
Across 12 payments — averaging $4456.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kala Pharmaceuticals, Inc.$44K
- Bausch Health US, LLC$9K
- Ocular Therapeutix, Inc.$500
What the payments were for
- Food & beverage$1,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 5 | $212 |
| AbbVie(2 entities) | 4 | $145 |
| NEW World Medical,inc. | 2 | $138 |
| Genentech USA, Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 7 | $117 |
| Ocular Therapeutix, Inc. | 3 | $111 |
| Novartis | 4 | $80 |
| Thea Pharma Inc. | 4 | $74 |
| Omeros Corporation | 3 | $58 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Aerie Pharmaceuticals, Inc. | 3 | $46 |
| Rayner Intraocular Lenses Limited | 2 | $39 |
| Shire North American Group Inc | 1 | $25 |
| Akorn, Inc. | 1 | $23 |
| Carl Zeiss Meditec USA, Inc. | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$133
- Kahook Dual Blade$125
- Clearpath$125
- Ahmed Glaucoma Valve$125
- Streamline$125
- VABYSMO$125
How this compares
$1,284 in reported general payments places this provider in the 40th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $13,322 |
| Alphagan PBrimonidine Tartrate | 23 | $11,591 |
| Prednisolone Acetate | 256 | $7,962 |
| Brimonidine Tartrate | 67 | $6,894 |
| Travoprost | 18 | $5,058 |
| MoxifloxacinMoxifloxacin Hcl | 169 | $4,231 |
| Latanoprost | 327 | $3,952 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,290 |
| Ketorolac Tromethamine | 75 | $2,334 |
| Cyclosporine | 12 | $1,926 |
| Timolol Maleate | 62 | $661 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 40 | $485 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 54 | $430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P | $145 | $24,91340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$1.8M
- Gregory ParkhurstSan Antonio$185K
- James LehmannSan Antonio$162K
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.